Bonerge Launches Second-Gen Amuctive™ Akkermansia, Shifting Focus from Bacterial Count to Active Protein Potency

SupplySide Global 2025 Preview - Booth No. 4331-1

NEW YORK--(BUSINESS WIRE)--Ahead of its showcase at the upcoming SupplySide Global 2025 ingredient exhibition, Bonerge is set to introduce a significant advancement in probiotic supplementation: the second-generation Amuctive™ Akkermansia muciniphila. This launch marks a strategic pivot for the industry, moving beyond merely counting bacterial colonies to ensuring the potency of a key active protein, Amuc_1100.

The development addresses a common consumer frustration: despite the recognized benefits of Akkermansia for metabolic and gut health, many existing supplements fail to deliver results. Bonerge's innovation targets the root cause—the discrepancy between high bacterial counts and low biological activity.

From "Live vs. Pasteurized" to "Active vs. Inactive"

Traditional Akkermansia supplements often revolved around the debate of live versus pasteurized bacteria. While live Akkermansia faces challenges like shelf stability, sensitivity to antibiotics, and potential safety concerns in certain populations, research indicated that properly pasteurized Akkermansia could be more effective. Bonerge's solution builds on this finding, emphasizing that the true source of Akkermansia's benefits is not the bacterium itself, but the robust Amuc_1100 protein present on its membrane, which remains active after pasteurization.

This protein acts as the primary effector molecule, responsible for supporting immune function, regulating glucose and lipid metabolism, and protecting the gut barrier. Without sufficient Amuc_1100, high bacterial counts are effectively "empty shells," offering little therapeutic value.

Second-Gen Amuctive™ Akkermansia: Quantifying Activity

The core innovation of the second-generation Amuctive™ Akkermansia lies in its proprietary production and quality control processes, specifically designed to maximize and verify Amuc_1100 content.

• Enhanced Potency: Through a patented fermentation and inactivation process, Bonerge achieves an Amuc_1100 protein content verified to be 2.5 to 7.6 times higher than conventional Akkermansia ingredients.

• Measurable Quality: The company has developed a proprietary detection technology to accurately quantify Amuc_1100 levels throughout production. This ensures consistent activity from batch to batch, a critical step towards reliable efficacy.

• Safety and Validation: The ingredient holds US SA-GRAS certification and is backed by multiple patents and internal studies demonstrating benefits for metabolic health and aging.

SSW Showcase and Broader Portfolio

At SupplySide Global 2025 (Booth No. 4331-1), Bonerge will highlight this next-generation Akkermansia as part of its broader portfolio of high-quality anti-aging ingredients. The exhibit will also feature other innovative compounds, including Fisetin, Urolithin A, S-Equol, L-Ergothioneine, and PQQ, underscoring the company's focus on science-backed, clinically relevant solutions for healthy aging.

In addition, Bonerge will sponsor a featured session at the Product Development Theater titled “Discover the Next Generation of Akkermansia muciniphila.” Presented by nutrition expert Jim Roufs, MS, RD, the talk will explore why certain Akkermansia supplements show limited efficacy and how Amuctive™ achieves measurable results through its patented process and elevated Amuc_1100 protein content. The session will take place on October 29, 2025, from 3:00–3:20 PM at Booth #8076.

Bonerge emphasizes that its commitment to "Safety" and "Efficacy" is embodied in the second-gen Amuctive™ Akkermansia, transforming an intangible concept—"activity"—into a measurable and controllable quality parameter. This launch is poised to set a new standard for probiotic and postbiotic supplements, shifting the industry's focus from quantity to proven potency.